{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:58:29Z","timestamp":1788537509602,"version":"build-2803163510"},"reference-count":82,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2023.2643","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:11:03Z","timestamp":1683202263000},"source":"Crossref","is-referenced-by-count":18,"title":["Development, efficacy and side effects of antibody\u2011drug conjugates for cancer therapy (Review)"],"prefix":"10.3892","volume":"18","author":[{"given":"Te","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Qun","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"key20230614063344_b1-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","article-title":"Tumor-treating fields: A fourth modality in cancer treatment","volume":"24","author":"Mun","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20230614063344_b2-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int J Oncol"},{"key":"key20230614063344_b3-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/82_2014_427","article-title":"The use of anti-CD40 mAb in cancer","volume":"405","author":"Remer","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20230614063344_b4-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf"},{"key":"key20230614063344_b5-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"4764","key":"key20230614063344_b6-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"8869","key":"key20230614063344_b7-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65860-x","article-title":"Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer antibody-drug conjugates (ADCs)","volume":"10","author":"Hoffmann","year":"2020","journal-title":"Sci Rep"},{"key":"key20230614063344_b8-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu Rev Med"},{"key":"key20230614063344_b9-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20230614063344_b10-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J Pharm Sci"},{"issue":"45","key":"key20230614063344_b11-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"520","key":"key20230614063344_b12-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"e1395127","key":"key20230614063344_b13-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2017","journal-title":"Oncoimmunology"},{"key":"key20230614063344_b14-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"MAbs"},{"key":"key20230614063344_b15-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nchem.2415","article-title":"Recent advances in the construction of antibody-drug conjugates","volume":"8","author":"Chudasama","year":"2016","journal-title":"Nat Chem"},{"key":"key20230614063344_b16-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/acschembio.8b00107","article-title":"A switchable site-specific antibody conjugate","volume":"13","author":"Lyu","year":"2018","journal-title":"ACS Chem Biol"},{"key":"key20230614063344_b17-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"561","key":"key20230614063344_b18-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20230614063344_b19-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"key20230614063344_b20-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"key20230614063344_b21-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov Today Technol"},{"key":"key20230614063344_b22-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J"},{"key":"key20230614063344_b23-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J Cell Physiol"},{"issue":"93","key":"key20230614063344_b24-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u2018biological missile\u2019 for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20230614063344_b25-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/tcr.202100054","article-title":"Antibody glycoengineering and homogeneous antibody-drug conjugate preparation","volume":"21","author":"Manabe","year":"2021","journal-title":"Chem Rec"},{"issue":"107917","key":"key20230614063344_b26-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"5510","key":"key20230614063344_b27-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: The new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20230614063344_b28-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"key20230614063344_b29-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1634\/theoncologist.2019-0025","article-title":"The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia","volume":"24","author":"Ali","year":"2019","journal-title":"Oncologist"},{"issue":"872","key":"key20230614063344_b30-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"McKertish","year":"2021","journal-title":"Biomedicines"},{"key":"key20230614063344_b31-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: An emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"key20230614063344_b32-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"24","key":"key20230614063344_b33-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark Res"},{"key":"key20230614063344_b34-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.htct.2020.07.008","article-title":"Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed\/refractory acute leukemia prior to hematopoietic cell transplant: A case series","volume":"43","author":"Fatobene","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"key":"key20230614063344_b35-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2018.205948","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: Act 2, with perhaps more to come","volume":"104","author":"Hitzler","year":"2019","journal-title":"Haematologica"},{"key":"key20230614063344_b36-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"key20230614063344_b37-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br J Haematol"},{"key":"key20230614063344_b38-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20230614063344_b39-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key20230614063344_b40-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-Year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"key20230614063344_b41-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"key20230614063344_b42-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"key20230614063344_b43-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-018-0100-0","article-title":"Rapid desensitization for brentuximab vedotin (Adceteris\u00ae) allergy: A case report","volume":"16","author":"Di Girolamo","year":"2018","journal-title":"Clin Mol Allergy"},{"issue":"88","key":"key20230614063344_b44-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: Clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"key20230614063344_b45-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/jnci\/djaa140","article-title":"Breast cancer screening trials: Endpoints and overdiagnosis","volume":"113","author":"Jatoi","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"102286","key":"key20230614063344_b46-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key20230614063344_b47-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J Cell Physiol"},{"issue":"102033","key":"key20230614063344_b48-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102033","article-title":"HER2-positive advanced breast cancer treatment in 2020","volume":"88","author":"Cesca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20230614063344_b49-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/toxins3070848","article-title":"Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components","volume":"3","author":"Dosio","year":"2011","journal-title":"Toxins (Basel)"},{"key":"key20230614063344_b50-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/10781552211015772","article-title":"Trastuzumab-emtansine induced pleural and pericardial effusions","volume":"27","author":"Lombardi","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"1758835920962997","key":"key20230614063344_b51-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920962997","article-title":"An overview of antibody-drug conjugates in oncological practice","volume":"12","author":"Theocharopoulos","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"key20230614063344_b52-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/tbj.12906","article-title":"Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience","volume":"24","author":"Okines","year":"2018","journal-title":"Breast J"},{"issue":"12760","key":"key20230614063344_b53-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49251-5","article-title":"Real-world data on T-DM1 efficacy-results of a single-center retrospective study of HER2-positive breast cancer patients","volume":"9","author":"Hardy-Werbin","year":"2019","journal-title":"Sci Rep"},{"issue":"37","key":"key20230614063344_b54-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0633-6","article-title":"Antibody-drug conjugates in breast cancer: A comprehensive review","volume":"20","author":"Pond\u00e9","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"key20230614063344_b55-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1111\/bcp.13381","article-title":"Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with \u22652 HER2-targeted regimens","volume":"83","author":"Chen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"89","key":"key20230614063344_b56-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00089","article-title":"Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients","volume":"8","author":"Larionov","year":"2018","journal-title":"Front Oncol"},{"issue":"517","key":"key20230614063344_b57-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5687-0","article-title":"Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine \u00b1 pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer","volume":"19","author":"Perez","year":"2019","journal-title":"BMC Cancer"},{"key":"key20230614063344_b58-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"issue":"110407","key":"key20230614063344_b59-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110407","article-title":"T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives","volume":"129","author":"Liu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"key20230614063344_b60-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20230614063344_b61-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"key":"key20230614063344_b62-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"key20230614063344_b63-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"key20230614063344_b64-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20230614063344_b65-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-Month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"2861","key":"key20230614063344_b66-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25122861","article-title":"Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: A drug-delivery perspective","volume":"25","author":"Dahlgren","year":"2020","journal-title":"Molecules"},{"key":"key20230614063344_b67-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ijc.32408","article-title":"[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int J Cancer"},{"issue":"4774","key":"key20230614063344_b68-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20230614063344_b69-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10120-021-01164-x","article-title":"Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: A clinical perspective","volume":"24","author":"Aoki","year":"2021","journal-title":"Gastric Cancer"},{"key":"key20230614063344_b70-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","article-title":"Trastuzumab deruxtecan (DS-8201a): The latest research and advances in breast cancer","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"key20230614063344_b71-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"111682","key":"key20230614063344_b72-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: Trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"key20230614063344_b73-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"key20230614063344_b74-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"key20230614063344_b75-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1758835920986518","key":"key20230614063344_b76-MCO-18-6-02643","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920986518","article-title":"Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer","volume":"13","author":"Kotani","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"key20230614063344_b77-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"key20230614063344_b78-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14712598.2021.1890710","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond","volume":"21","author":"Perez","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"key20230614063344_b79-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"key":"key20230614063344_b80-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20230614063344_b81-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"key20230614063344_b82-MCO-18-6-02643","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T06:33:51Z","timestamp":1686724431000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2023.2643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2023.2643","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"article-number":"47"}}